Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination

X. Tong, R. P. McNamara, M. J. Avendaño, E. F. Serrano, T. García-Salum, C. Pardo-Roa, H. L. Bertera, T. M. Chicz, J. Levican, E. Poblete, E. Salinas, A. Muñoz, A. Riquelme, G. Alter () and R. A. Medina ()
Additional contact information
X. Tong: MIT, and Harvard
R. P. McNamara: MIT, and Harvard
M. J. Avendaño: Pontificia Universidad Católica de Chile
E. F. Serrano: Pontificia Universidad Católica de Chile
T. García-Salum: Pontificia Universidad Católica de Chile
C. Pardo-Roa: Pontificia Universidad Católica de Chile
H. L. Bertera: MIT, and Harvard
T. M. Chicz: MIT, and Harvard
J. Levican: Pontificia Universidad Católica de Chile
E. Poblete: Pontificia Universidad Católica de Chile
E. Salinas: Pontificia Universidad Católica de Chile
A. Muñoz: Pontificia Universidad Católica de Chile
A. Riquelme: Pontificia Universidad Católica de Chile
G. Alter: MIT, and Harvard
R. A. Medina: Pontificia Universidad Católica de Chile

Nature Communications, 2023, vol. 14, issue 1, 1-15

Abstract: Abstract Since the emergence of SARS-CoV-2, vaccines targeting COVID-19 have been developed with unprecedented speed and efficiency. CoronaVac, utilising an inactivated form of the COVID-19 virus and the mRNA26 based Pfizer/BNT162b2 vaccines are widely distributed. Beyond the ability of vaccines to induce production of neutralizing antibodies, they might lead to the generation of antibodies attenuating the disease by recruiting cytotoxic and opsonophagocytic functions. However, the Fc-effector functions of vaccine induced antibodies are much less studied than virus neutralization. Here, using systems serology, we follow the longitudinal Fc-effector profiles induced by CoronaVac and BNT162b2 up until five months following the two-dose vaccine regimen. Compared to BNT162b2, CoronaVac responses wane more slowly, albeit the levels remain lower than that of BNT162b2 recipients throughout the entire observation period. However, mRNA vaccine boosting of CoronaVac responses, including response to the Omicron variant, induce significantly higher peak of antibody functional responses with increased humoral breadth. In summary, we show that vaccine platform-induced humoral responses are not limited to virus neutralization but rather utilise antibody dependent effector functions. We demonstrate that this functionality wanes with different kinetics and can be rescued and expanded via boosting with subsequent homologous and heterologous vaccination.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-023-39189-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39189-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-39189-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().